Intravenous Fosaprepitant Versus Oral Aprepitant for Children Receiving Highly Emetogenic Chemotherapy: An Investigator‐Initiated Randomized, Open‐Label, Non‐Inferiority Trial

Key Points

• To compare the efficacy of intravenous fosaprepitant and oral aprepitant in children receiving highly emetogenic chemotherapy.
• Investigator-initiated randomized trial
• Open-label design
• Children receiving highly emetogenic chemotherapy
• Participants administered either intravenous or oral antiemetic
• No significant difference in efficacy between intravenous fosaprepitant and oral aprepitant
• Both treatments effectively managed chemotherapy-induced nausea and vomiting